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Scott A RivkeesAbstract
The most prevalent cause of thyrotoxicosis in children is Graves’ disease (GD), and remission occurs only in a
modest proportion of patients. Thus most pediatric patients with GD will need treatment with radioactive iodine
(RAI; 131I) or surgical thyroidectomy. When antithyroid drugs (ATDs) are prescribed, only methimazole (MMI) should
be administered, as PTU is associated with an unacceptable risk of severe liver injury. If remission does not occur
following ATD therapy, 131I or surgery should be contemplated. When 131I is administered, dosages should be
greater than 150 uCi/gm of thyroid tissue, with higher dosages needed for large glands. Considering that there
will be low-level whole body radiation exposure associated with 131I, this treatment should be avoided in young
children. When surgery is performed near total or total-thyroidectomy is the recommended procedure. Complications
for thyroidectomy in children are considerably higher than in adults, thus an experienced thyroid surgeon is needed
when children are operated on. Most importantly, the care of children with GD can be complicated and requires
physicians with expertise in the area.
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Graves’ disease (GD) is the most common cause of
hyperthyroidism in children and is a considerably more
pernicious condition than hypothyroidism. The preva-
lence of GD is 1 in 1,000 adults [1] and is 1 in 10,000 in
the pediatric population [2]. GD is due to thyroid gland
stimulation by thyroid receptor antibodies [TRAbs; or
thyroid stimulating immunoglobulins (TSI)] [3]. Toxic
nodules, toxic multinodular goiters, acute and subacute
thyroiditis, thyroid hormone ingestion can also cause
childhood thyrotoxicosis, but much less commonly than
GD [4].
Symptoms of hyperthyroidism include excessive phys-
ical activity, tremor, tachycardia, flushing, palpitations,
weight loss, accelerated linear growth, reduced bone
mineralization, and poor school performance [4]. In
childhood GD, ophthalmopathy occurs in less than 50%
of patients and is usually mild when present [4].
Because GD spontaneously resolves uncommonly,
hyperthyroidism treatment is mandatory. Therapeutic ap-
proaches for GD include the antithyroid drugs (ATDs)Correspondence: srivkees@ufl.edu
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unless otherwise stated.propylthiouracil (PTU) or methimazole (MMI), radioactive
iodine (131I), or surgery [4-7]. Each of these modalities has
uniquely associated benefits and risks that must be con-
sidered when children are treated.Antithyroid drugs
ATDs were introduced in the 1940s with thiouracil being
the first compound used clinically [8]. Because of the
high incidence of toxic reactions associated with thioura-
cil, this medication was replaced for clinical use by PTU
in 1947 [8]. MMI became a treatment option for GD in
1950 [8].
ATDs act by inhibiting oxidation and organic binding
of thyroid iodide to impair thyroid hormone production
[9]. MMI is ten- to twenty-fold more potent than PTU
and has a longer half-life [9]. Importantly, these medica-
tions do not cure the hyperthyroid state, rather they palli-
ate the condition. Each of these medications is associated
with adverse events that must be considered when pre-
scribed. As such, prior to the initiation of ATD therapy, a
back-up plan that takes into account the patient’s age and
treatment risks, in the event that a toxic reaction occurs,
should be considered.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In 2008, a number of serious complications associated
with PTU therapy in children were brought to public
attention by Rivkees [10-12]. PTU-induced liver injury at
that time accounted for 15% of liver transplants in the
United States [13]. From 1990 to 2007, 23 PTU-related
liver transplants took place, and 30% of the PTU-related
transplant recipients were children. Based on prescrib-
ing data, the risk of PTU-induced liver failure leading
to transplantation was estimated to be 1 in 2,000 chil-
dren [2].
Despite a common perception, because PTU-induced
liver injury occurs rapidly and is often irreversible, serial
monitoring of transaminase levels in a child on PTU, is
not viewed to be useful in helping to reduce drug hepato-
toxicity risk [2]. As such, the only way to reduce the risks
of PTU-related hepatotoxicity is to avoid the use of the
medication.
In 2009, Rivkees and Madison recommended that PTU
not be used in children, and that PTU be stopped in all
children taking the medication in favor of alternative
treatments [11]. In April, 2010, the US Food and Drug
Administration issued a black box regarding the use of
PTU stating that PTU should not be used in children
[10], except in special settings, solidifying the notion
that the drug should not be used.
Appropriate limited use of propylthiouracil
Although PTU should be avoided clinically, there is a
role for its limited use in special circumstances. PTU can
be used when neither prompt 131I or surgical treatment
are options in a patient who has had a toxic reaction to
MMI, and ATD medication is necessary. In this situation,
PTU should only be used short-term while plans for 131I
or surgery are developed.
When PTU is used, patients and guardians need to be
informed of the risk of liver failure and to be alert for
signs and symptoms of liver abnormalities. These features
include pruritus, jaundice, anorexia, light colored stools,
dark urine, and abdominal pain. If these problems occur,
the patient should immediately stop the medication, a
practitioner contacted, and laboratory tests obtained
(white blood cell count, bilirubin, alkaline phosphatase,
ALT/AST).
Methimazole
MMI is now the drug-of-choice for GD. Carbimazole,
which is a pro-drug that is converted to MMI, can be used
in place of MMI in countries where it is available. Al-
though MMI is often prescribed in divided doses over the
day, once a day dosing is sufficient [14] and is associated
with better compliance than multiple daily doses [15]. The
typical MMI dose is 0.2 to 0.5 mg/kg per day, and doses
can range from 0.1 to 1.0 mg/kg per day [3,16-20].MMI is available in 5, 10, and 20 mg tablets. When
used in children, the following doses that are fractions of
tablets can be used: infants, 1.25 mg per day; 1 to 5 years,
2.5 to 5.0 mg/day; 5 to 10 years, 5 to10 mg/day; and 10
to 18 years, 10 to 20 mg/day. When there is severe
hyperthyroidism, one can use double the above doses.
Because the hyperthyroid state can be associated with
low white cell counts and patients will be treated with a
medication that can depress neutrophil levels, it is reason-
able to obtain a complete blood count at therapy onset. In
addition, we routinely obtain transaminase levels and liver
function tests at therapy onset, to assess for premorbid
liver disease, as we find that 1% of our patients may have
autoimmune hepatitis.
The response to ATDs influencing circulating thyroid
hormone levels is not instantaneous, and several months
are needed for thyroid hormone levels to normalize
[7,14]. Thyroid function tests should thus be obtained
monthly after therapy onset. After T4 levels become
normal, the MMI doses can be cut by half to maintain
euthyroidism [21]. Because TSH levels may take months
to normalize, they should not be used to guide changes
in medication in early phases of treatment.
Rather than titrating the MMI dose lower when circu-
lating thyroid hormone levels fall, some physicians prefer
the block-and-replace approach and add levo-thyroxine
while not changing the MMI dose, however, there is a
greater risk of adverse events using block and replace vs.
dose reduction [21,22]. Recognizing that there is a poten-
tial dose–response relationship for some MMI-related
complications [23,24], it is preferable to use the lowest
MMI dose that achieves control, rather than using the
block and replace approach.
Although MMI is the drug of choice for GD, MMI
therapy is not without risks. Minor side effects may
affect up to 17% of children [25]. The most common
minor adverse side effects related to MMI are hives, arth-
ralgia, and neutropenia [25]. Children may also develop
major side effects, including Stevens-Johnson syndrome
and vasculitis [25]. MMI adverse events most commonly
occur within 6 months of therapy onset [25]. Yet, 4% of
children will develop adverse events 18 months of MMI
therapy, highlighting the need for constant vigilance while
on treatment.
Agranulocytosis is another potential serious ATD
adverse event and occurs in 0.3% of adults taking PTU
or MMI [7,26]. With MMI, agranulocytosis is dose-
dependent and is rare at low doses [7,26]. If an individual
receiving MMI feels ill, becomes febrile or develops
pharyngitis, MMI should be stopped immediately, a
practitioner contacted, and a complete blood cell count
obtained.
Agranulocytosis typically develops first 3 months of
therapy [7,26]. Thus, whereas it is tempting to treat with
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be avoided. Rather, relatively lower doses of MMI should
be employed initially, and symptoms managed with beta-
blockers. Furthermore, the time to normalization of thy-
roid function tests is only modestly different in individuals
treated with high vs. low ATD doses [14].
Although ATDs can be used long-term, reports describe
the development of anti-neutrophil-cytoplasmic antibodies
(ANCAs), which are associated with vasculitis and may
limit prolonged medical therapy of GD [27-29]. In adults
up to 15% of individuals treated with PTU, develop ANCAs
after 2 years of therapy [27,28]. MMI use is also associated
with ANCA-positivity conversion, albeit with a lower
incidence than with PTU [27,28].
In the pediatric population, ANCA-mediated disease has
been observed with either PTU or MMI [30,31] . Because
these antibodies can trigger serious vasculitis events, an-
tithyroid medications should be stopped and definitive
therapy considered when ANCA antibodies are detected
[32]. To test for this potential problem it is reasonable
to perform annual assessment of ANCAs on children on
prolonged ATD therapy, i.e. more than two years.
Duration of therapy
Remission of GD is defined as being biochemically euthyr-
oid or hypothyroid for one year or more after the discon-
tinuation of ATDs. The collective literature indicates that
remission rates in children are less than 25% following
many years of ATD therapy [33-37] (Table 1).
Although prolonged ATD treatment will control bio-
chemical hyperthyroidism, it is not clear that prolonged
ATD use increases the likelihood of lasting spontaneous
remission [38]. In a French study of 94 patients, following
treatment for 6 or 18 months, remission rates were 42%
and 62% respectively, after two years of treatment [39].
In 52 Spanish patients, following treatment for 12 or
24 months, remission rates were 46% and 54%, respect-
ively, 2 years after cessation of therapy [40]; at 5-years,
the relapse rate was 85%. Another study of 134 French
patients found no benefit of 18 vs. 43 months of treat-
ment [41]. Thus treating beyond 18 months does not
increase remission likelihood in adults.Table 1 Studies of rates of remission related to
antithyroid drug use
Author Date Sample Outcome* Reference
Hamburger 1985 262 14% [54]
Glaser 1997 184 24% [34]
Glaser 2008 58 29% [35]
Kaguelidou 2008 154 28% [36]
Leger 2012 154 48% [37]
*Remission rate.In the pediatric age group, remission rates range from
20 to 30% following ATDs use for two years or more
[18,35,36,42,43]. More than 25 years ago, Lippe and co-
workers estimated that 25% of children go into remission
for every two years of treatment [44]. Of the 63 patients
followed on ATDs, 36 (57%) remitted after an average of
four years of therapy [44]. Yet, there were little data to
show if the patients who came off ATDs remained in
remission [44].
Other large cohort studies of ATD use for many years
[33,34] show low remission rates. Of more than 200 chil-
dren with GD in Minnesota, 25% were in remission after
one year; 25% after 2 years; 26% after 4 years; and 15%
after 10 years. In addition, 30% of the boys and girls who
went into remission had disease recurrence [33].
When 184 pediatric children in California were followed
for up to 4 years, the overall remission rate was 23% [34].
After one year of ATDs, 10% were in remission; after
2 years, 14% were in remission; after 3 years, 20%) were in
remission; and after 4 years, 23% were in remission.
In a study of children in Argentina, 113 patients re-
ceived ATDs for prolonged periods [45]. After 10 years
of treatment, 33% of patients treated with ATDs went
into remission [45].
Most recently, a study performed in France reported
that prolonged drug therapy was associated with 50%
remission rates in children [37]. One-hundred fifty-four
children with GD diagnosed between 1997 and 2002 were
examined following treatment with carbimazole. The esti-
mated rates of remission were 20%, 37%, 45%, and 49%,
after 4, 6, 8, and 10 years of therapy, respectively [37].
Age-related factors also influence remission likelihood.
In a study of 32 prepubertal vs. 68 pubertal children with
GD, remission occurred in 17% of prepubertal children
treated for 6 years vs. 30% of pubertal children [42]. In
another report with pre- and post-pubertal cohorts, re-
mission occurred in 28% of children [46], but the time
to remission was three-times longer in the pre-pubertal
children than pubertal children [46]. Of note, adverse
reactions to ATDs occurred with greater frequency in
prepubertal children (71%) than in pubertal (28%) and
postpubertal (25%) children [46].
In addition to puberty, TRAb levels and gland size in-
fluence remission rates. The efficacy of ATDs is inversely
related to circulating levels of TRAbs. Remission rates of
GD in adults are about 15% in patients high TRAb levels
at diagnosis, and 50% when the pretreatment levels are
normal [47]. Large glands at presentation are also associ-
ated with much lower remission rates than when gland
size is normal [48-50].
Symptomatic management
In patients treated with ATDs for GD, it may take one or
two months until biochemical hyperthyroidism resolves
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propranolol, atenolol or metoprolol, can be used to control
GD symptoms. When the patient has asthma, metoprolol is
preferred over non-selective beta-blockers, with the patient
carefully monitored [51]. When thyroid hormone levels
normalize, beta blockers can be stopped.
Metabolic complications of GD
Increasing evidence shows that GD can be associated
metabolic complications. GD can be associated with either
hyper- or hypoglycemia at presentation [52,53]. Myopathy
has been observed both at initial presentation and when
hypothyroidism occurs after therapy [54]. Excessive weight
gain has been observed after initiation of therapy, leading
to the recommendation that dietary counseling take place
when treatment is initiated [55].
Radioactive iodine
Radioactive iodine uptake by the thyroid is not distin-
guishable from ordinary iodine, thus radioactive iodine
is trapped in thyroid cells [56]. After being taken up by
thyroid cells, beta-emissions bring about the destruc-
tion of the iodine trapping-cells and those in close
proximity [56].
Around ten different isotopes of iodine have been used
in medicine. 123I is the isotope most frequently used for
diagnostic studies of thyroid structure and function [56].
121I has a short half-life (13.3 hrs) and emits x-rays and
gamma-photons, but no beta particles. By comparison,
131I has a half-life of 6–8 days and emits beta particles and
gamma rays.
Radioactive iodine use for thyroid ablation was intro-
duced in the 1940’s at the Massachusetts Institute of
Technology and Massachusetts General Hospital [6,57].
When the US Atomic Energy Commission was permitted
to supply uranium fission products for medical usage, 131I,
with an eight-day half-life became available for GD treat-
ment. Because of the intrinsic advantages a longer half-life
isotope, 131I quickly became the favored iodine isotope for
treating thyroid cancer and hyperthyroidism.
Treatment approach
The goal for 131I therapy for GD is to induce
hypothyroidism. Radioactive iodine should not be given to
cause euthyroidism in children, as this results in partially-
irradiated residual thyroid tissue that will be associated with
a risk of thyroid neoplasm [58,59]. It has been suggested
that dosages delivering 30,000 to 40,000 cGy (rad) to the
thyroid are necessary to ablate the thyroid gland [60,61];
however, doses delivering 10,000 to 20,000 cGy to the thy-
roid are more often used and result in partial or complete
destruction of the thyroid [4,62,63].
Typically, administered thyroid doses of 150 uCi/gm
(5.5 MBq/gm) generate radiation doses of 12,000 cGy tothe thyroid [64]. After 131I treatment, radiation exposure
to the stomach, marrow, liver, and gonads is about 14,
6.8, 4.8, and 2.5 cGy per organ, respectively, with total
body exposure at about 4.0 cGy [64]. Because of fetal risks,
131I should not be given to women who are pregnant.
The rate of iodine uptake and the amount of thyroid
tissue present influences thyroid destruction potential.
Dosages of radioiodine administered are thus based on
iodine uptake and gland size using the Quimby-Marinelli
equation: dosage (radiation; in Gy) = 90 × oral iodine-131
dose (μCi) × oral 24-hr uptake (%) / gland mass (gm) ×
100%). This calculation assumes an effective T/1/2 of
6.0 days for 131I. Thyroid size is estimated by palpation or
ultrasound (ultrasound volume = 0.48 × length × depth ×
width) [65]. If a patient is taking antithyroid medication,
treatment should be stopped 3–5 days before radioactive
iodine is administered. After 131I administration, the circu-
lating levels of thyroid hormones may increase within 4 to
10 days, as thyroid hormone is released from degenerating
follicular cells [66]. Thus if antithyroid medication is dis-
continued too soon, there can be accumulation of excess
thyroid hormone within the gland, leading to an increased
risk of thyroid storm following treatment [67].
It usually takes 6 to 12 weeks after 131I treatment for the
patient to become biochemically euthyroid or hypothyroid.
Until then, symptoms of hyperthyroidism can be controlled
using beta-blockers [66,68,69]. The use of SSKI or Lugol’s
solution one week after 131I will also quickly attenuate bio-
chemical hyperthyroidism without adversely affecting the
outcome of radioiodine therapy [69].
In as many as 5% of patients, receiving properly calcu-
lated dosages, hyperthyroidism will persist after 131I. It is
recommended that these patients receive a second dose
of radioiodine [62], which can be given 6 months after
initial therapy. Furthermore, sometimes in those patients
with residual thyroid tissues, as indicated by being eu-
thyroid or borderline hypothyroid, hyperthyroidism may
recur requiring additional therapy.
Cure rates are higher in patients treated with larger
than smaller amounts of 131I. When treated with relatively
low dosages (50–75 uCi/gm), hyperthyroidism persists in
30 to 50% of adults one year after therapy [70-73]. By
comparison, after treatment with higher dosages (150–250
uCi/gm), only 5-10% of patients will remain hyperthyroid
at one year [64,74,75].
Radioiodine therapy’s success is influenced by the thy-
roid gland size and by circulating levels of TRAb. Patients
with very large glands (>80 gm) and high TRAb levels
have lower responses to 131I therapy than patients with
smaller glands [63,76-79]. Because of poor response rates
with very large glands, thyroidectomy should be consid-
ered for individuals with glands greater than 80 gm. But, if
131I is used in this setting, patients should be counseled
that the risk of needing an additional dose, will be higher
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cal removal of very large glands will be associated with
greater risk than removal of a smaller gland.
Considering the above, patients treated for GD need
to be constantly monitored for progressive thyromegaly,
which can change a patients from being an excellent
candidate for good 131I outcome, to one in which outcomes
is poor or associated with increased risks of therapy. Gland
size can be grossly estimated by palpation, with the exam-
iner standing behind the patient and feeling each lobe of
the thyroid gland with their index fingers to estimate the
size of each lobe relative to a teaspoon (5 gm) or tablespoon
(15 gm), or multiples thereof. For example if each lobe of
the thyroid is about one teaspoon, the estimated gland size
is 10 gm. Yet, when there are about two tablespoons or
more for each lobe, gland size will be 60 gm or more.
When the gland is large, thyroid ultrasound is recom-
mended to more accurately assess gland size. By ultra-
sound gland size is 0.6 × length × width × depth [80,81].
Radioactive iodine use in children
Several studies have reported the details of 131I therapy
for childhood GD [33,82-88]. Children as young as one
year old have been treated with 131I with excellent results
[88,89]. But, treatment of such young children is not com-
mon, nor is recommended. 131I dosages in children and
teenagers have ranged from 100 to 400 uCi/gm of thyroid
tissue [4]. Similar to that found in adults, responses to 131I
therapy are related to gland size and dose. 25 to 40% of
children treated with 50–100 uCi of 131I per gm of thyroid
tissue are hyperthyroid several years after therapy [58]. In
children treated with 150–200 uCi of 131I per gm thyroid,
hyperthyroidism remains in 5-20%, and 60-90% become
hypothyroid [4,62,83,89].
Our group analyzed outcomes of the children treated
with radioactive iodine therapy to assess the effectiveness
of therapy as related to gland size and dose [90]. Following
treatment, when treated with 80–120 uCi of 131I per
gm of thyroid tissue, 28% of children were hyperthy-
roid, 28% of children were euthyroid, and 42% of
children were hypothyroid. Following treatment with
200–250 uCi per gm of thyroid tissue, 37% of chil-
dren were hyperthyroid and 62% were hypothyroid.
Following, treatment with 300–400 uCi per gm of thyroid
tissue, 0% of children were hyperthyroid, euthyroid, and
93% were hypothyroid. Comparing these pediatric data
with those from adults [63,65,90], thyroid tissue of chil-
dren appears to be more sensitive to 131I induced ablation
than adults.
As in adults, we find that gland size influences therapy
outcomes. In general, higher dosages per gm of thyroid
tissue are needed with larger than smaller glands. Yet,
with glands larger than 80 gm, 131I efficacy is low and is
not recommended.As in adults, when children are to be treated with 131I,
ATDs should be stopped 3 to 5 days prior to treatment
[90]. Patients are then placed on beta-blockers until T4
and/or free T4 levels normalize post-therapy. Whereas
some clinicians restart ATDs after treatment with 131I,
this is rarely required in children [4,62,90,91]. Thyroid
hormone levels begin to decrease about 7 days after
radioiodine therapy in children and continued ATD use can
make it difficult to assess if post-treatment hypothyroidism
is the result of 131I or the ATD.
Some centers give a fixed administered dosage of 10 or
15 mCi 131I to all children [91] rather than individually
calculated administered activation. There are no studies
comparing outcomes of fixed doses vs. calculated doses in
children. In adults, the two different approaches lead to
similar outcomes [92,93]; however, in children, a potential
advantage of calculated vs. fixed dosing, is that it might be
possible to use lower dosages of 131I if the administered
dose is calculated.
Side effects of 131I therapy are unusual. Less than 10%
of children will complain of mild tenderness over the
thyroid in the first week after 131I therapy. This can be
treated with either acetaminophen or non-steroidal,
anti-inflammatory agents for 24 to 48 hrs [62,90].
There are rare reports of children with severe hyperthy-
roidism developing thyroid storm after 131I [67]. In general,
these children were severely hyperthyroid when 131I was
rendered. Thus, if T4 levels are >20 ug/dl (200 nmol/l) or
freeT4 levels are >5 ng/dl (60 pmol/l), children should be
treated with MMI until T4 and/or free T4 levels normalize
before proceeding with 131I therapy [90]. It is important to
recognize that most children with GD have been hyperthy-
roid for months prior to diagnosis; there is no need to rush
to 131I therapy.
Following 131I, T3, T4 and/or free T4 levels should be
obtained monthly. Because TSH levels may be suppressed
for several months after the hyperthyroid state is corrected.
Thus, TSH determination may not be useful post-therapy.
Typically, hypothyroidism develops by 2 to 3 months after
treatment [90,91]. When T4 levels fall below normal, levo-
thyroxine is prescribed.
Ophthalmopathy
The development of progression of ophthalmopathy fol-
lowing 131I in adults has been reported. However, unlike
adults, children rarely develop severe ophthalmopathy
and proptosis is mild.
Studies show that disease worsens in only a small per-
centage of children with GD, irrespective of therapy type.
Of 87 children treated with 131I for GD at one center,
proptosis improved in 90% of children, did not change in
7.5%, and worsened in 3% post-therapy [75,89]. In 45 chil-
dren who had ophthalmopathy at the onset of treatment
at another center, eye disease improved in 73% and
Table 2 Total cancer and cancer mortality related to 131I
therapy for hyperthyroidism in adults
Author Date Site Sample Outcome Reference
Ron 1998 US 23,020 No Effect*** [109]
Holm 1991 SW 10,000 No Effect** [107]
Franklyn 1998 UK 7,209 No Effect [104]
Flynn 2006 UK 3,888 No Effect [103]
Metso 2007 FN 2,793 No Effect* [108]
Franklyn 2005 UK 2,668 No Effect [105]
Goldman 1982 US 1,762 No Effect [106]
***Increase in thyroid CA with Nodular Disease.
**20% increase in stomach CA.
*15% Increase in stomach CA in Elderly Men with Nodular Disease.
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[94]. After subtotal thyroidectomy in 80 children, eye
disease was worsened in 9% [95], and was stable in 75%
after total surgical thyroidectomy [95].
In adults, it has been shown that progression of
ophthalmopathy can be prevented by treatment with
prednisone for 3 months following 131I therapy [96].
Adjunctive prednisone therapy is not routinely recom-
mended for the majority of children, as most do not
have significant eye disease. The prolonged administra-
tion of prednisone is also associated with growth failure,
weight gain and immune suppression. Nevertheless,
prednisone may be useful for the child who has severe
eye disease and will be treated with 131I.
The risks of genetic damage with radioactive iodine
There is no evidence showing adverse effects to offspring
of children treated with 131I. Birth defects were not higher
in 500 offspring born to about 370 individuals treated
with 131I for hyperthyroidism during childhood or ado-
lescence [4]. Additionally, the rates of birth defects are
not higher in children treated with 80–700 mCi of 131I
for thyroid cancer, which are dosages that are much
higher than those used for GD [97].
Thyroid neoplasm risk with radioactive iodine
The thyroid gland is unique in its developmental sensitivity
to malignancy after low-level radiation exposure [98-101].
There is an increased risk of thyroid cancer in individuals
less than 20 years of age at the time of low-level thy-
roid irradiation, and the younger one is, the greater the
thyroid cancer risk [98-100]. In contrast, individuals
who are older than 20 years of age, do not exhibit an
increased risk of thyroid cancer when exposed to low-level
thyroid irradiation [98-101].
Importantly, the risk of thyroid neoplasms is great-
est with exposure to low-level external radiation
(0.1-25 Gy; ~0.09-30 uCi/gm) [98-102] and not with
the higher dosages used to treat GD. At present, we are
not aware of any cases of thyroid cancer that developed in
pediatric patients treated with >150 uCi of 131I per gm
of thyroid tissue for childhood GD that can be attrib-
uted to 131I therapy. Thus, it is important that low dosages
be avoided.
Non-thyroid cancer risks with radioactive iodine
Along with the risk of thyroid cancer, the potential in-
fluences of 131I therapy on other cancers must be con-
sidered since 131I therapy results in low-level, whole
body radiation exposure. Several studies in adults have
examined potential risks of 131I therapy for GD on can-
cers (Table 2). These studies have not revealed increased
mortality or increased rates of cancer following 131I for
GD [103-109].In comparison with studies in adults, few studies have
focused on outcomes of 131I therapy for childhood GD.
The most extensive study of pediatric patients involved
36 year outcomes of 116 patients who were less than
20-years old when treated with 131I therapy for GD
[110]. There was no evidence for increase cancer risk in
this population.
The total-body radiation dose after 131I varies with
age, and the same absolute dose of 131I will result in
more radiation exposure in a young child than in an
adolescent or adult [111,112]. Currently, we do not have
dosimetry data on 131I use in pediatric patients with GD
to assess total body exposure in pediatric patients. Based
on phantom modeling, it is estimated that at 0, 1, 5, 10,
15 years, and adulthood, respective total body radiation
doses will be 11.1, 4.6, 2.4 1.45, 0.90, and 0.85 rem
(0.01 Sv) per mCi of 131I administered [111,112]. Based on
the Biological Effects of Ionizing Radiation Committee V
(BEIR VII) analysis of low-level, acute exposure to radi-
ation [113], theoretical lifetime attributable risk of cancer
mortality and all cancer incidence can be projected. Based
on these theoretical calculations, we feel that it is prudent
to avoid radioactive iodine therapy in children under
5 years of age and to avoid >10 mCi in patients less than
10 years old. Yet, these recommendations are based on
theoretical concerns and not on hard data.
We recognize that there may be circumstances
when 131I therapy is necessary for young children. The
need for 131I in a young child may occur when the child
develops a toxic reaction to an ATD, proper surgical ex-
pertise is not accessible, or the child is not a suitable surgi-
cal candidate.
Surgery
The oldest form of definitive GD therapy is surgery, with
the Nobel Prize in Physiology and Medicine awarded in
1909 to Koker for developments in this area. When sur-
gery is considered, near total or total-thyroidectomy is
indicated, as subtotal thyroidectomy is associated with a
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versal in children and adults who undergo total thy-
roidectomy [95,114-116]. In comparison, after subtotal
thyroidectomy, hyperthyroidism recurs in 10-15% of
patients [95,114,115].
Surgery is preferred in children younger than 5 years
when definitive therapy is needed AND can be performed
by a skilled thyroid surgeon. In individuals who have
large thyroid glands (>80 gm), the response to 131I is
poor [63,117]. Thus, surgery is recommended for these
patients.
In preparation for surgery, the patient should be ren-
dered euthyroid. Typically, this is done by continuing
MMI until T4 levels normalize. A week before surgery,
iodine drops are started (5 to 10 drops, t.i.d.), which in-
hibits thyroid hormone production and causes the gland
to become firm and less vascular, facilitating surgery.
Postoperatively, younger pediatric patients are at a higher
risk for transient hypoparathyroidism than adolescents
or adults [118]. To mitigate post-operative hypocalce-
mia, we treat children with 0.5 mcg of calcitriol, twice a
day, for 3 days prior to surgery. Post-operatively, the
calcitriol is weaned over 15 days (0.5 mcg bid × 5 days;
0.5 mcg qd × 5 days; 0.5 mcg qod x 5 days) [119]. Using
this approach only 5% of patients require post-operative
calcium infusions vs. 40% of patients without preopera-
tive treatment [119].
Complications of surgery
Acute complications that follow thyroidectomy include
hemorrhage, hypocalcaemia, and recurrent laryngeal
nerve paresis [118,120-123]. In children, rates from 0–6
years were 22%, from 7–12 years, 11%; and from 13 to
17 years, 11% [118]. These rates are higher than those in
adults.
Complication rates are also related to the type of
surgeon. When performed by pediatric surgeons, the
complication rate for total thyroidectomy is approximately
15%. In comparison, the complication rate in children for
high-volume thyroid surgeons (>30 thyroidectomies/year)
is approximately 4%.
Considering these data, if local pediatric thyroid sur-
gery expertise is unavailable, referral of a child with GD
to a high-volume, thyroid surgery center with pediatric
experience should be considered [124,125]. Very low
complication rates for children undergoing the thyroid-
ectomies for GD have been reported with this type of
multidisciplinary model [119,124].
Conclusions
Based on what we know about both the risks of different
treatments and the pathogenesis of GD, we can be dis-
criminating in our approach to therapy. To reduce the
risks of treatment and to expedite cure, treatment shouldbe guided by the patient’s age, the nature of the intrinsic
autoimmune disease, and by expertise.
For children less than 5 years old, MMI should be
considered as a first-line therapy. While radioactive
iodine has been successfully used in this age group
without an apparent increase in cancer rates [89,126],
it may be wisest to defer radioactive iodine therapy
until older.
Because young children are less likely to have remission
on drug treatment vs. older children [42,46], prolonged
drug therapy may be necessary. Assuming there are no
toxic effects, continuing MMI is sensible until the child is
old enough for 131I. If reactions to medication develop, or
there is the desire to avoid prolonged drug use, thyroidec-
tomy or 131I can be considered. Fortunately, less than 5%
of children with GD present at 5 years or younger [127].
It is important to emphasize that when ATDs are used,
only MMI should be prescribed. PTU use should be re-
stricted to special circumstances when neither prompt
surgery nor 131I treatments are possibilities in a patient
who has developed a toxic reaction to MMI, and ATD
therapy is required. In this setting, the use of PTU
should be short-term.
Fifteen percent of children with GD will present be-
tween 6 years and 10 yrs of age [127]. It is reasonable
to consider MMI therapy as a first line measure for this
age group. As 10 years of age is approached, either
drug therapy or radioactive iodine can be considered
as an initial therapy.
Children who are 10 years and older account for 80%
of the pediatric GD cases. Radioactive iodine or MMI
can be considered as first line treatment options for this
age group. TRAb levels and thyroid size may be predictive
of remission rates. The presence of low TRAb levels and a
small thyroid is suggestive of the possibility of spontan-
eous remission after at least one year of medical therapy.
Yet, if the thyroid is large and TRAb levels are high, the
odds of spontaneous remission are low [47,128,129].
For those patients who have normal TRAb levels and
a small thyroid, it is reasonable to treat for one to two
years and stop the drug when clinical remission is
achieved. If relapse occurs, medical treatment can be
resumed or an alternative form of therapy chosen. For
patients with elevated TRAb levels and a large thyroid
size, it is less likely that remission will occur after medical
therapy. Thus, definitive treatment soon after euthyroid-
ism is achieved can be considered.
When radioactive iodine is used, it is important that
the appropriate dosage be administered. The objective
of radioactive iodine therapy in pediatric patients
should be to ablate the thyroid gland and achieve
hypothyroidism. The risk of thyroid cancer will be very
small, if present at all, if no thyroid tissue remains, To
achieve this objective, doses of 131I >150 uCi/gm of
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larger glands.
Finally, regardless of the treatment option selected,
careful follow up is essential for all patients treated for
GD. Long-term follow-up should include, once or twice
a year, regular examination of the thyroid gland and
measurement of circulating levels of thyroid hormones.
Selecting a treatment approach for childhood GD can
be challenging and personal decision. It is essential that
physicians discuss the advantages and risks of each thera-
peutic option to help the patient and family select the
treatment plan they feel comfortable with.
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